Sarepta Therapeutics | SRPT - Собственный капитал и резервы





Собственный капитал и резервы Изменить Дата
Acadia Pharmaceuticals USD 1.25B 20.68M 2026-03
Agios Pharmaceuticals USD 1.11B 84M 2026-03
Alnylam Pharmaceuticals USD 1.08B 286.2M 2026-03
Amgen USD 9.19B 532M 2026-03
BioCryst Pharmaceuticals USD -553.84M 434.69M 2026-03
Biogen USD 18.65B 394.9M 2026-03
BioMarin Pharmaceutical USD 6.21B 125.11M 2026-03
Capricor Therapeutics USD 278.7M 27.09M 2026-03
Daiichi Sankyo JPY 1.71T 57.86B 2025-12
Eli Lilly USD 31.2B 4.66B 2026-03
Esperion Therapeutics USD -307.93M 5.97M 2026-03
Gilead Sciences USD 23.52B 897M 2026-03
Incyte USD 5.62B 455.37M 2026-03
Insmed USD 704.85M 34.12M 2026-03
Ionis Pharmaceuticals USD 491.41M 2.32M 2026-03
Moderna USD 7.41B 1.24B 2026-03
Nektar Therapeutics USD 89.83M 4.75M 2025-12
Neurocrine Biosciences USD 3.41B 154.3M 2026-03
Novavax USD -144.76M 17.01M 2026-03
Pfizer USD 90.1B 3.63B 2026-03
PTC Therapeutics USD -180.46M 24.85M 2026-03
Regeneron Pharmaceuticals USD 31.42B 166.7M 2026-03
Roche Holding CHF 33.8B 758M 2025-12
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Sanofi EUR 72.81B 1.1B 2026-03
Sarepta Therapeutics USD 1.51B 364.48M 2026-03
Tectonic Therapeutic USD 230.42M 20.91M 2026-03
Ultragenyx Pharmaceutical USD -236M 156M 2026-03
Vertex Pharmaceuticals USD 19.36B 696.1M 2026-03